Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Has Appetite For Obesity: Firm To License Solvay Phase I Cannabinoid Antagonist

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies will jointly develop and commercialize SLV319. Potential inroad into obesity market aligns with Bristol's long-term focus on "high-potential disease areas," company says.
Advertisement

Related Content

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says
Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar
Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar
Sanofi Plans To Add Two NMEs To Phase III In 2004, Bringing Total To Nine

Topics

Advertisement
UsernamePublicRestriction

Register

PS059422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel